The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation

NCT ID: NCT06864052

Last Updated: 2025-03-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-01
• Study Completion Date: 2029-12-31

Brief Summary

This study aims to determine whether there is a difference in brain lesion occurrence and safety when brain MRI is followed up between edoxaban and apixaban in stroke patients with nonvalvular atrial fibrillation through exploratory clinical trials.

Detailed Description

This study is a prospective open randomized clinical trial that can confirm which group the subject was assigned to.After randomization, either the test group or the control group is prescribed, and the outcome variable is checked at 24 months. Therefore, patients who were previously administering edoxaban and apixaban can participate in the study, but if a patient who is administering edoxaban is assigned to apixaban, the drug is taken as apixaban, and similarly, if a patient who is administering apixaban is assigned to an edoxaban, the drug is changed to edoxaban and taken. During clinical trials, testers and researchers carefully observe the occurrence of adverse reactions during the follow-up period after randomization, and closely observe outcome variables, including neurological changes. During the clinical trial period, visits are made after 6, 12, 18, and 24 months, respectively, to check the signs of physical vitality, drug history, side effects, and other research-related events, and brain MR is performed at the 24th month to check the effectiveness and safety. Brain MR can be performed for various reasons before 24 months.In the brain image performed 24 months ago, if the drug is changed or stopped for a long time, the tester plans to first implement appropriate medical measures and then determine whether to continue this study. This clinical trial is a prospective open study and will be conducted in compliance with the usual diagnosis and treatment process, and in particular, all subjects will be properly tested and treated in accordance with the standard treatment guidelines for ischemic stroke during the clinical trial.

Subjects may receive active treatment according to the standard treatment guidelines for ischemic stroke during the clinical trial. In stroke patients with nonvalvular atrial fibrillation, NOAC administration is itself a standard practice guideline, so participating in this study does not deviate from the standard treatment guidelines for stroke at all. In principle, when all planned visits are completed, the subject's participation in the clinical trial will be terminated.

Conditions

Stroke; Atrial Fibrillation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Administration of Apixaban

The intervention group will receive Apixaban 2.5mg or Apixaban 5mg

Group Type: EXPERIMENTAL

Administration of Apixaban

Intervention Type: DRUG

Apixaban 2.5mg BID or Apixaban 5mg BID

Administration of Edoxaban

The control group will receive Edoxaban 15mg or 30mg or 60mg

Group Type: OTHER

Administration of Edoxaban

Intervention Type: DRUG

Edoxaban 15mg QD or Edoxaban 30mg QD or Edoxaban 60mg QD

Interventions

Administration of Apixaban

Apixaban 2.5mg BID or Apixaban 5mg BID

Intervention Type: DRUG

Administration of Edoxaban

Edoxaban 15mg QD or Edoxaban 30mg QD or Edoxaban 60mg QD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Aged 19 or over.

2. Patients who are neurologically stable 14 days after diagnosis of ischemic stroke and who have undergone brain MRI (including MR diffusion, FLAIR, and GRE sequence) at diagnosis of ischemic stroke (In general, the patient's condition stabilizes within seven days of acute cerebral infarction, but cerebral infarction with atrial fibrillation is more frequent than patients without atrial fibrillation, so we want to target patients with neurological stability after 14 days. Most NOAC-related clinical trials were conducted when the patient's condition became neurologically stable at least two weeks after the stroke.)

3. Patients with atrial fibrillation confirmed by 12-lead electrocardiogram or Holter's examination for more than 24 hours and nonvalvular atrial fibrillation

4. A person who voluntarily agrees to participate in this clinical trial in writing

Exclusion Criteria

1. Patients unable or contraindicated to administer anticoagulants and antithrombotic agents

2. Patients with less than 80,000 platelets, less than 8.0 hemoglobin, liver levels, and total bilirubin levels three times the normal level in the laboratory

3. A person who is confirmed to be undergoing renal replacement treatment such as dialysis due to acute or terminal nephropathy during screening

4. A person who has been diagnosed with cancer within 6 months at the time of screening or has been treated for cancer has been confirmed to have recurrent or metastatic cancer.

5. A person who has been confirmed to be taking medication for liver diseases such as liver cirrhosis during screening

6. A person who is pregnant and nursing. However, women of childbearing age can participate only if it is certain that they are not pregnant. Women of childbearing age are defined as women except those who have not clearly undergone menopause or are unable to conceive by surgical procedures.

7. A patient with a history of hemorrhagic tendencies, gastrointestinal hemorrhage

8. Patients who have difficulty explaining and expressing their opinions on participation in the study due to decreased consciousness at the time of acquisition of consent

9. A person who judges that the tester is not appropriate for participation in the clinical trial for other reasons.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ewha Womans University Seoul Hospital

OTHER

Sponsor Role: lead

Responsible Party

Tae-Jin Song, MD, PhD

Cerebrovascular hospital, the director of a hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Ewha Womans University Medical Center

Seoul, Seoul, South Korea

Countries

South Korea

Central Contacts

Sujin Han Clinical Research Coordinator

Role: CONTACT

sujinhan1004@gmail.com

82-2-6986-2635

Facility Contacts

Tae Jin Song, MD

Role: primary

knstar@ewha.ac.kr

82269863307

Other Identifiers

SEUMC 2024-08-070

Identifier Type: -

Identifier Source: org_study_id